Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has announced the launch of a spin-off company, Breathe Biologics, Inc., aimed at commercializing technologies for COPD. TSOI has licensed its assets, including an Investigational New Drug Application (IND) from the FDA, now known as “Allogeneic Umbilical Cord Mesenchymal Stem Cells, JadiCell.” This innovative stem cell therapy showcases potential in treating COPD and was highlighted by Dr. James Veltmeyer as having remarkable effects on inflammatory diseases. The company's president, Timothy Dixon, is optimistic about rapid commercialization and its positive impact on patients.

Positive

• Launch of Breathe Biologics, Inc. to commercialize COPD technologies.
• FDA granted IND for JadiCell, indicating regulatory approval for clinical development.
• Potential for JadiCell to address significant unmet medical need in COPD treatment.

Negative

• None.

Phase III Clinical Trial Stem Cell Company Aims to Fast Forward Regenerative Solutions to Dreaded Lung Disease

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area of COPD.

Therapeutic Solutions International has licensed to Breathe Biologics assets in the COPD space including the Investigational New Drug Application (IND) which has been granted FDA number 28508. With the IND, the FDA assigned the stem cell therapy the new name of “Allogeneic Umbilical Cord Mesenchymal Stem Cells, JadiCell; Intravenous injection.”

COPD is marked by lung inflammation and damage to alveoli — the tiny air sacs in the lungs responsible for gas exchange. The precursor cells that line the alveoli, called alveolar epithelial progenitor cells, cannot adequately respond to this damage by generating enough new alveoli. JadiCells are mesenchymal stem cells (MSCs) — a type of adult stem cell found in several tissues that can give rise to many different cell types. MSCs possess anti-inflammatory, neuroprotective, and regenerative properties that have made them increasingly popular as potential therapeutic avenues for some conditions.

“The effects of JadiCell on numerous types of inflammatory disease are profound. In my personal experience, in patients with COVID-19 under Right to Try and Emergency Use IND, the results are nothing short of miraculous,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “To date regenerative medicine has not been truly applied to the problem of COPD, I am excited to assist Breathe Biologics in accelerating this novel technology to address a significant unmet medical need.”

“Through selecting opinion leaders in science and business and providing them with new and clinically applicable technologies I believe that we can extract significant value from our Innovation Factory at Therapeutic Solutions International,” said Timothy Dixon, President, and CEO of the Company. “I look forward to the rapid commercialization of the JadiCell for COPD which we believe will have a significant impact on patients.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005594/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What is the purpose of the new company Breathe Biologics, Inc. launched by TSOI?

Breathe Biologics, Inc. aims to commercialize technologies related to COPD.

What is JadiCell and why is it significant for TSOI?

JadiCell is an allogeneic umbilical cord mesenchymal stem cell therapy approved by the FDA for clinical use in COPD treatment.

What are the potential benefits of JadiCell for COPD patients?

JadiCell may have regenerative properties that can address inflammation and lung damage associated with COPD.

Who is leading the commercialization efforts for JadiCell?

Timothy Dixon, President and CEO of TSOI, is leading the commercialization efforts for JadiCell.